Overview

Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)

Status:
Completed

Trial end date:
2018-04-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of improvement of anemia in patients diagnosed with low- or intermediate-1 risk myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia (CMML).

Phase:

Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Immunoglobulin G